Madhavan Balachandran has served as a member of our Board since September 2017. Mr. Balachandran served as a director of Catalent, Inc. (NYSE: CTLT) from May 2017 to January 2024. Mr. Balachandran was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome Company, a predecessor before mergers of GlaxoSmithKline plc. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo, a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology, Bombay, and an MBA from East Carolina University.
What is Madhavan Balachandran's net worth?
The estimated net worth of Madhavan Balachandran is at least $857.23 thousand as of June 20th, 2025. Mr. Balachandran owns 37,697 shares of uniQure stock worth more than $857,230 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Balachandran may own. Learn More about Madhavan Balachandran's net worth.
How do I contact Madhavan Balachandran?
Has Madhavan Balachandran been buying or selling shares of uniQure?
Madhavan Balachandran has not been actively trading shares of uniQure within the last three months. Most recently, Madhavan Balachandran sold 2,112 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a transaction totalling $30,518.40. Following the completion of the sale, the director now directly owns 37,697 shares of the company's stock, valued at $544,721.65. Learn More on Madhavan Balachandran's trading history.
Who are uniQure's active insiders?
uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Leonard Post (Director), and Jeannette Potts (Insider). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?
In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 432,748 shares worth more than $13,686,033.43. The most recent insider tranaction occured on November, 6th when Director Robert Gut sold 31,434 shares worth more than $856,890.84. Insiders at uniQure own 4.8% of the company.
Learn More about insider trades at uniQure. Information on this page was last updated on 11/6/2025.
